CSL Stock

CSL Enterprise Value

The Enterprise Value (EV) of CSL (CSL.AX) as of Sep 10, 2026 is 56.80 B USD. In the previous year, Enterprise Value (EV) was 57.98 B USD — a change of -2.04% (lower).

Enterprise Value

56.80 BUSD

YoY

-2.04%

Last updated:

Enterprise Value (EV) of CSL is 2026 56.80 B USD. Enterprise Value (EV) of CSL was 2025 57.98 B USD. It decreases by -2.04% lower compared to the previous year.

The CSL Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
51.02 B USD
Jan 1, 2019
51.46 B USD
Jan 1, 2020
52.25 B USD
Jan 1, 2021
51.45 B USD
Jan 1, 2022
46.67 B USD
Jan 1, 2023
58.12 B USD
Jan 1, 2024
57.98 B USD
Jan 1, 2025
56.80 B USD
The CSL Enterprise Value history
YEAREnterprise ValueYoY
56.80 BUSD-2.04%
57.98 BUSD-0.25%
58.12 BUSD+24.54%
46.67 BUSD-9.28%
51.45 BUSD-1.53%
52.25 BUSD+1.54%
51.46 BUSD+0.85%
51.02 BUSD+0.88%
50.58 BUSD+1.08%
50.04 BUSD+1.76%
49.18 BUSD+0.90%
48.74 BUSD
Access this data via the Eulerpool API

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CSL stock

Enterprise Value (EV) of CSL is 56.80 B USD in 2026.

Enterprise Value (EV) of CSL changed from 57.98 B USD to 56.80 B USD, representing a -2.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) CSL since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s CSL with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — CSL

All Key Metrics — CSL